Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radiation therapy: are we getting value for money?

M B Barton1, V Gebski, C Manderson

  • 1Department of Radiation Oncology, Westmead Hospital, Sydney, Australia.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|January 1, 1995
PubMed
Summary

Radiotherapy (RT) is a cost-effective cancer treatment, offering a lower cost per life year gained (LYG) compared to other modalities. This study analyzed RT

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial.

ESMO gastrointestinal oncology·2026
Same author

Dynamic Contrast-enhanced Magnetic Resonance Imaging Evaluation of Whole Tumour Perfusion Heterogeneity Predicts Distant Disease-free Survival in Locally Advanced Rectal Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2022
Same author

Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma.

BMC cancer·2022
Same author

The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Actual Versus Optimal Radiotherapy Utilisation for Metastatic Cancer Patients in the 45 and Up Study Cohort, New South Wales.

Clinical oncology (Royal College of Radiologists (Great Britain))·2021
Same author

Patterns of palliative radiotherapy fractionation for brain metastases patients in New South Wales, Australia.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2020

Area of Science:

  • Oncology
  • Health Economics
  • Radiotherapy Research

Background:

  • Cancer treatment necessitates evaluating the long-term cost-effectiveness of various therapeutic modalities.
  • Radiotherapy (RT) is a cornerstone in cancer management, requiring economic assessment.
  • Understanding the cost per life year gained (LYG) is crucial for efficient healthcare resource allocation.

Purpose of the Study:

  • To determine the long-term cost-effectiveness of radiotherapy (RT) in cancer treatment.
  • To calculate the cost per life year gained (LYG) for RT services.
  • To compare the cost-effectiveness of RT with other cancer treatment strategies.

Main Methods:

  • Kaplan-Meier survival analysis was used to calculate average survival and total life years.
  • Costing data for RT fields, including capital, operational, and labor costs, were compiled.
  • Cost per life year gained (LYG) was calculated, with sensitivity analysis performed on survival and cost estimates.

Main Results:

  • A total of 9868 patients received RT between 1980 and 1993, with a median survival of 2 years.
  • The total cost of RT during the study period was $54,219,097 (1993 dollars), yielding a cost per life year of $1157.
  • The cost per life year gained (LYG) for RT was $7186, with sensitivity analysis showing a range of $3920 to $15,632.

Conclusions:

  • Radiotherapy (RT) demonstrates a favorable cost per life year gained (LYG) compared to other established cancer treatments.
  • The findings support RT as an efficient treatment modality, aiding in resource allocation decisions.
  • Further cost-effectiveness analyses of other major cancer treatment modalities are recommended.

Related Experiment Videos